Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...
Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...
Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...
X Leveraged ETFs for Rocket Lab and Hims & Hers ●RKLX, the Defiance Daily Target 2X Long RKLB ETF, seeks daily investment ...
Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...
Hims and other telehealth companies make finasteride easy to get and don’t have to disclose side effects in ads.
Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...
Former US Army Sgt. Mark Millich’s sex drive plummeted — and his genitals shrank and changed shape after taking popular hair-loss drug finasteride.
We recently compiled a list of the 10 Best Skincare Stocks to Buy According to Hedge Funds. In this article, we are going to ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results